Magazine Article | February 1, 2019

Foreign Investors Trigger ‘Critical Technology' Review for Biotech

Source: Life Science Leader

By Gail Dutton, Contributing Writer
Follow Me On Twitter @GailLdutton

U.S. biotech companies that receive foreign investments and are developing critical technologies or the components that enable those technologies now might have to file mandatory declarations with the Committee on Foreign Investment in the U.S. (CFIUS). The new rules apply to investors from any foreign country — and apply even if the investor does not take a controlling interest in the company.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: